Gordon Heidkamp

Gordon Heidkamp

Auto-generated profile, based on publicly available information

Gordon Heidkamp

Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center, Munich, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Molecular Cell
Verified
Journal Article
Closed access
ECElsa Callén
Elsa Callén
MJMila Jankovic
Mila Jankovic
NWNancy Wong
Nancy Wong
SZShan Zha
Shan Zha
HCHua-Tang Chen
Hua-Tang Chen
MNMichel Nussenzweig
Michel Nussenzweig

7 April 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CLChristian Lehmann
Christian Lehmann
ABAnna Baranska
Anna Baranska
GHGordon F. Heidkamp
Gordon F. Heidkamp
LHLukas Heger
Lukas Heger
KNKirsten Neubert
Kirsten Neubert
DDDiana Dudziak
Diana Dudziak
Dendritic cells (DCs) are efficient antigen-presenting cells equipped with various cell surface receptors for the direct or indirect recognition of pathogenic microorganisms. Interestingly, not much is known about the specific expression pattern and function of the individual activating and inhibitory Fcγ receptors (FcγRs) on splenic DC subsets in vivo and how they contribute to the initiation of T cell responses. By targeting antigens to select activating and the inhibitory FcγR in vivo, we show that antigen uptake under steady-state conditions results in a short-term expansion of antigen-specific T cells, whereas under inflammatory conditions especially, the activating FcγRIV is able to induce superior CD4+ and CD8+ T cell responses. Of note, this effect was independent of FcγR intrinsic activating signaling pathways. Moreover, despite the expression of FcγRIV on both conventional splenic DC subsets, the induction of CD8+ T cell responses was largely dependent on CD11c+CD8+ DCs, whereas CD11c+CD8− DCs were critical for priming CD4+ T cell responses.

9 January 2025 in Blood
Verified
Journal Article
Open access
PDF file
JEJan Eckmann
Jan Eckmann
TFTanja Fauti
Tanja Fauti
MBMarlene Biehl
Marlene Biehl
AZAintzane Zabaleta
Aintzane Zabaleta
LBLaura Blanco
Laura Blanco
PUPablo Umaña
Pablo Umaña
Despite several approved therapies, multiple myeloma (MM) remains an incurable disease with high unmet medical need. “Off-the-shelf” T-cell bispecific antibodies (TCBs) targeting B-cell maturation antigen (BCMA) and G protein–coupled receptor class C group 5 member D (GPRC5D) have demonstrated high objective response rates in heavily pretreated patients with MM; however, primary resistance, short duration of response, and relapse driven by antigen shift frequently occur. Although GPRC5D represents the most selective target in MM, recent findings indicate antigen loss occurs more frequently than with BCMA. Thus, anti-GPRC5D immunotherapies must hit hard during a short period of time. Here, we characterize forimtamig, a novel GPRC5D-targeting TCB with 2+1 format. Bivalent binding of forimtamig to GPRC5D confers higher affinity than classical 1+1 TCB formats correlating with formation of more stable immunological synapses and higher potency in tumor cell killing and T-cell activation. Using an orthotopic mouse model of MM, forimtamig recruited T effector cells to the bone marrow and induced rapid tumor killing even after the introduction of step-up dosing to mitigate cytokine release. Combination of forimtamig with standard-of-care agents including anti-CD38 antibodies, immunomodulatory drugs, and proteasome inhibitors improved depth and duration of response. The combination of forimtamig with novel therapeutic agents including BCMA TCB and cereblon E3 ligase modulatory drugs was potent and prevented occurrence of GPRC5D -negative tumor relapse. Forimtamig is currently being evaluated in phase 1 clinical trials in patients with relapsed and refractory MM for monotherapy and in combination treatments. This trial was registered at www.ClinicalTrials.gov as #NCT04557150.